跳至主要内容
临床试验/JPRN-UMIN000004175
JPRN-UMIN000004175已完成未知

Study of oral neurokinin-1 antagonist, aprepitant for prevention of nausea and emesis in patients receiving chemotherapy including cisplatin for gastric cancer. - Effect of aprepitant in patient recieving chemotherapy including cisplatin for gastric cancer.

Division of gastroenterologic surgery, Kanazawa University0 个研究点目标入组 55 人开始时间: 2010年10月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
55

研究概览

简要总结

Addition of aprepitant to standard antiemetic therapy was effective in gastric cancer patients undergoing treatment with cisplatin and S-1.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) patients with serious hepatic insufficiency or renal failure. 2) patients with emesis within 24 hours before first administrating of cisplatin. 3) patients who were administered antiemetic drugs within 48 hours before first administrating of cisplatin. 4) patients with emetic factor except for chmotherapy 5) patient who was intended radiation therapy 6) patients judged inappropriate for this study by physicians. 7) patients who received Pimozide.

研究者

发起方
Division of gastroenterologic surgery, Kanazawa University

相似试验